Transforming the Treatment Landscape in Early NSCLC

Julia K. Rotow, MD


September 06, 2022

Julia K. Rotow, MD, discusses issues in the management of early-stage non–small cell lung cancer (NSCLC) — including the challenge of making a diagnosis at the earliest stage, when curative therapy is still an option. Dr Rotow sees the expansion of lung cancer screening programs as a transformative means to identify more patients at an earlier stage.

With the advent of biomarker testing in patients with early-stage NSCLC after initial diagnosis, Dr Rotow considers personalized biomarker-directed therapy to be another major advancement in the treatment landscape of early-stage NSCLC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.